Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma N
Fiche publication
Date publication
août 2016
Journal
Lancet (London, England)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CASASNOVAS Olivier, Pr FEUGIER Pierre
Tous les auteurs :
Hermine O, Hoster E, Walewski J, Bosly A, Stilgenbauer S, Thieblemont C, Szymczyk M, Bouabdallah R, Kneba M, Hallek M, Salles G, Feugier P, Ribrag V, Birkmann J, Forstpointner R, Haioun C, Hänel M, Casasnovas RO, Finke J, Peter N, Bouabdallah K, Sebban C, Fischer T, Dührsen U, Metzner B, Maschmeyer G, Kanz L, Schmidt C, Delarue R, Brousse N, Klapper W, Macintyre E, Delfau-Larue MH, Pott C, Hiddemann W, Unterhalt M, Dreyling M,
Lien Pubmed
Résumé
Mantle cell lymphoma is characterised by a poor long-term prognosis. The European Mantle Cell Lymphoma Network aimed to investigate whether the introduction of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation (ASCT) improves outcome.
Mots clés
Adult, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Combined Modality Therapy, Cyclophosphamide, therapeutic use, Cytarabine, administration & dosage, Doxorubicin, therapeutic use, Female, Hematopoietic Stem Cell Transplantation, methods, Humans, Immunosuppressive Agents, administration & dosage, Immunotherapy, Lymphoma, Mantle-Cell, drug therapy, Male, Middle Aged, Prednisone, therapeutic use, Transplantation Conditioning, Treatment Failure, Vincristine, therapeutic use
Référence
Lancet. 2016 Aug;388(10044):565-75